Iovance Biotherapeutics Inc. (NASDAQ:IOVA)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for IOVA
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- woodman: $IOVA is worth keeping on the radar as it tries to move up past the 50d.
- woodman: $IOVA - setting an alert for a cross above the 50d. On good volume would be nice, too.
- joelsg1: @woodman $AMGN $VKTX $ARDX $HUMA $IOVA My amulet Magic 8 ball is illegible :)
- woodman: @joelsg1 $AMGN $VKTX - For VKTX https://www.wikihow.com/Remove-Black-Magic-Spells Could work for $ARDX $HUMA and $IOVA as well. I very significantly lightened up on all of these, some completely out of now for the time being. HUMA I had lightened up ...
- MongosPawn: $IOVA Nice day trade.
- woodman: $IOVA trying to move out of some consolidation within uptrend.
- MongosPawn: @woodman $IOVA Long from below. Earning scheduled for after the close on 11/7 per TOS.
- woodman: @MongosPawn $IOVA - IOVA is also presenting data at the Society for Immunotherapy of Cancer on Friday-Saturday 11/8-11/9. I think of the 3 posters/abstracts it's presenting, one on Saturday could be a needle mover. Not entirely sure, though, if it wil move the needle.
- woodman: $IOVA movnig.
- woodman: $IOVA - I posted about this one yesterday metioning that it has some data coming via late-breaking abstracts to be presented 11/8-11/9, and in particular one that will provide updates for a Phase 2 lung cancer trial on 11/9. You can look back for tha ...
- kenb: @woodman $IOVA in this along with you, holding a nice size profitable position. Rode it all the way down, and riding it up again (I'm trying to get better at taking some profits near the highs and re-loading at lower levels and making some progress). In this case I didn't add even when it got close to my break-even afraid that it was going lower. Only a lost opportunity, but profitable on the trade. Good luck to us.
- MongosPawn: @woodman $IOVA Getting some love into the close.
- woodman: $IOVA - Check this out. Posted today by IOVA on Twitter. Of particular interest here is the late breaking abstract to be presented at the Society for Immunotherapy of Cancer annual meeting on 11/9 - updated results of Phase 2 data for its lifileucel plus pembrolizumab (Keytruda) for treatment of NSCLC (non-small cell lung cancer). I ask this: why would a company submit a very late-breaking abstract if the data aren't good? And this could be why the stock has moved over the last several days as people in the know moved on it. I bought some this afternoon and will watch it to see if it falls back a little for me to add. https://x.com/IovanceBio/status/1851635578422411387
- woodman: $IOVA trying again to move out of 1.5 month consolidation under the 200d. It has a couple failed attempts.
- kenb: $IOVA up 7% on no news.
- Onthemark: @kenb $IOVA Took a small starter yesterday at 10.07. Ready to add on a pullback bounce.
- MongosPawn: $IOVA Nice percentage bounce off of the 100dma with volume. Still has a lot of work to do.
- kenb: @MongosPawn $IOVA yes, nice action today and testing the 50d MVA from below on higher volume than the past few weeks. Watching to see if it can get above. And the 200d MVA is just above at $10.55 on my chart.
- woodman: $IOVA Day 6 of higher lows (with 5 days of higher highs) since coming off rising support a week ago.
- woodman: @woodman $IOVA - I hexed IOVA.
- woodman: $IOVA bounce continues. I bought yesterday. We'll see what happens when it hits the overhead 200d ($10.24). Last time it happened (8/9), it moved right up through and decently higher, but times befoe that (6/12, 7/25-26), it failed there.
- woodman: $IOVA move extending up through the 200d ... for now.
- woodman: $IOVA buying a little of this back.
- Dale: @woodman $IOVA Thanks. Was on my watch list. Bought back some shares at 9.50
- woodman: @Dale $IOVA - we just need to be careful that it holds this level. It's still under the 8dEMA.
- woodman: @Mikev200 $HUMA - I have no idea what that means, except that he can't say anything one way or another until FDA decides? Quite period? But here's a question for us all to ponder: Why the hell is Dougan still on the board if he has a lot of debt req ...
- Mikev200: @woodman $HUMA $IOVA I have NO idea what that means either! Just giving the info exactly as I have it. I agree in waiting for more clarity. I am also all out RHRN. I see some online saying Dugan sells a few million every month. I have NO idea. If I miss the first 1x so be it. Btw, do you know anything about the warrants $HUMAW? I can't find when they expire and at what price. Just thinking these might be better than holding calls at some point.
- woodman: @Mikev200 $HUMA $IOVA $HUMAW - I've seen RevShark discuss his trading of them, but I'm clueless on the warrants.
- kenb: $IOVA still dancing around the 8d EMA trying to decide on a direction.
- woodman: $IOVA bounce off 8dEMA following a pullback to it.
- woodman: $IOVA - I sold most of mine today. Not a pretty IOVA candle at present and biotech is discouraging across the board today. That said, it could hold the 8dEMA and end up being a good buy spot. Or, it could keep moving down to next test some prior ascending resistance that one could draw hitting around the 13dEMA. Regardless, I decided to take some profit rather than ride it lower.
- kenb: @woodman $IOVA had a nice rebound the last 2 weeks after the early Aug drop riding along the upper bollinger band, and as you say is down to and sitting on the 8dEMA as support for now. Depending on the market, it could bounce or drop lower. Probably a good idea to take profits if unsure, and congrats. For me the eternal optimist, I'm going to hold out for now and watch closely.
- woodman: @Mikev200 $HUMA #Biotech - Thanks, Mike. I remain long, though not quite as large a position as I once had. That's mainly because I implemented a stop after the delay issue arose and that was hit. I bought back shares, but some of that stopped money found its way into other of my the biotechs I hold, with a good chunk adding to $VKTX and buying $IOVA. But I do have a decent HUMA position. I just wish we had a better idea of timing.
- Onthemark: $IOVA doing well today past $12. Still has room to move higher to $13 following the 8dema.
- woodman: @Onthemark $IOVA - Actually the 5dEMA. It woudn't be the worst thing for it to let the 8dEMA to catch up. But, I think this has eyes on ~$14 and change in the short term. If it holds up there, and market conditions/the Fed cooperate, I think it could revisist its 2024 high of ~$18. I've been adding on the way up, and will likely be adding more.
- woodman: $IOVA up escalator.
- Onthemark: My favorites today: $SOND, $HUMA and $IOVA
- woodman: $ARDX $VKTX $IOVA - biotechs working this morning.
- MongosPawn: @woodman $ARDX $VKTX $IOVA Starter taken in $IOVA. Long the other two already. Perky.
- Bs7518: @woodman $ARDX $VKTX $IOVA Added to $IOVA yesterday Long from below $ADRX $VKTK
- woodman: @MongosPawn @Bs7518 $ARDX $VKTX $IOVA - Loving IOVA!
- kenb: @woodman $ARDX $VKTX $IOVA Loving all 3 in my portfolio, bio-techs working well lately. Thanks.
- woodman: $IOVA I continue to add on the way up. Added more today at $11.58. Not a great get today, but I've been buying in a couple accounts since moving above 8/9's intraday high. I don't really see any near-term resistance at this point. Maybe ~$14.20 as a next resistance/test/bump area.
- joelsg1: @woodman $IOVA Similar to $VKTX on takeover potential.
- woodman: @joelsg1 $IOVA $VKTX - I like that $IOVA has commercialized treatments and is being very aggressive pursuing treating doctors and hospitals.
- woodman: $IOVA - I wasn't around yesterday, but I added to mine this morning. It recently broke-out from a 2-month base following a big pullgack after the approval of its melanoma drug. And yesterday, it broke out from that flag I mentioned the other day. Lots of room to move higher on the chart. Fundamentally, it has a commercialized treatment for advanced melanoma for many patients with no alternative and who will die without the drug. It also has a treatment for metastatic renal cell carcinoma. And it has a deep pipeline as it examines the treatments for other types of cancer. The company is being very aggressive with its commercialized drugs as it gears up manufacturing and sales.
- woodman: $IOVA pushing back up to today's high.
- woodman: $IOVA - watch this next week. It's in a little high consolidation/flag and is holding the 200d after a recent move (this week) above the 200d from a lower, longer consolidation/base. The current move follows a good earnings/updates report on 8/8. It looks promising here, as it has moved up through descending resistance from 2/28, but it's right at shorter term rising resistance from 6/12, so we're not in the clear with this. But, a move above $10.94 - call it $11.00 - could provide the next leg up with decent room to move higher. I started a small-ish position this week.
- woodman: $IOVA interesting on the weekly.
- woodman: $IOVA - it reported on 8/8. Iovance Biotherapeutics (IOVA) reported a loss of $0.34 per share on revenue of $31.11 million for the second quarter ended June 2024. The consensus estimate was a loss of $0.37 per share on revenue of $26.01 million. The company beat consensus estimates by 8.11% while revenue grew 12,969.75% on a year-over-year basis. Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer.
- woodman: $IOVA I'm seeing short interest in the range of 20-25%.
- woodman: $IOVA has legs into the close (since about 3:20). More broadly, it is moving out of a base and looks more like a real move up through the 200d this time after 3 prior failed attempts since mid-June.
- kenb: @woodman $IOVA yeah, saw the action late in the day, however no news so I'm not sure what is going on. Acting very strongly after ER. Today's close puts it above the 20d bollinger bands, so will be watching for a little pull back to see if the $10 level will hold (today's low was $9.94). 50d MVA starting to curl up. I have a decent size long holding.
-
kenb: $IOVA up 6% AH on announcement.
SAN CARLOS, Calif. , May 23, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infil ... - Bs7518: @woodman do you see a catalyst for $IOVA in the near term? Thinking of adding.
- woodman: @Bs7518 $IOVA - IOVA has fallen off my radar. More generally, I significantly reduced my biotech exposure some weeks ago in this biotech-hostile market, and also because I was going on vacation and didn't want to have to look at them and fret. I hold ...
- Bs7518: @woodman $IOVA $VKTX $ARDX $XFOR $DAWN Thank you sir Glad your back
- MongosPawn: $IOVA Nice pullback, bounce off of the 21dma.
-
woodman: ...
Finally, I am watching $IOVA and would buy on a decent pullback if one developed. Currently, I have no position in IOVA. - MongosPawn: @woodman $ARDX $CLRB $XFOR $INZY $AQST $PDSB $MREO $VKTX $EFTR $IOVA #Biotechs Thank you for the update. Just to confirm, are you holding $AQST through earnings? I believe they report tonight. Thanks again.
- woodman: @MongosPawn $ARDX $CLRB $XFOR $INZY $AQST $PDSB $MREO $VKTX $EFTR $IOVA #Biotechs - Yes, and then through topline Phase 3 data for Anaphylm this month. It also has a PDUFA for another product - Livervant (ages 2-5) - on or before 4/28/24.
- woodman: @MongosPawn $ARDX $CLRB $XFOR $INZY $AQST $PDSB $MREO $VKTX $EFTR $IOVA #Biotechs - AQST presentation at Oppenheimer Healthcare Conference on 2/13/24. https://wsw.com/webcast/oppenheimer33/aqst/2800530
- woodman: @Lou - sold $IOVA, chased $AQST. As Lou - who is already in it - is likely aware, but others here may not be, this company is working on sublingual and similar delivery of meds. Some key dates are approaching. It has earnings on 3/5 (conf. call 3/6 8am), phase 3 data for sublingual film for epinepherine (Anaphylm) by end of March, and its PDUFA for its buccal film (in the cheeck) for its Libervant (diazepam for Breakthrough Seizures /Cluster Seizures, ages 2-5) on 4/28/2024. I'm pissed I didn't enter this last week when I read about it. But I needed to sell some stuff to buy it.
- Lou: @woodman $IOVA $AQST - I've sold a good number of lesser performing biotechs today but as still holding $ARDX $AQST $CLRB $INZY $IOVA $MREO and $VKTX. Added to my $VKTX exposure via short puts and rolled a few short $ARDX puts out and down for a little roll premium.
- kenb: $IOVA reporting earnings, and product roll out updates, today after close.
- Lou: Added a little to $IOVA AH RHRN at 16.7
- Lou: @woodman $EFTR $PDSB $MREO $XFOR $CLRB $INZY $ARDX - Thanks Woodie, I'm in all of them in varying amounts off your good work, as well as $AQST $IOVA $HUMA and $LFMD -
- woodman: @Lou $EFTR $PDSB $MREO $XFOR $CLRB $INZY $ARDX $AQST $IOVA $HUMA $LFMD - Good work with $AQST. I wanted to buy it yesterday, but I just don't have the available cash to add it to my arsenal. I think you will do well with it.
- Lou: @woodman $EFTR $PDSB $MREO $XFOR $CLRB $INZY $ARDX $AQST $IOVA $HUMA $LFMD Started buying the $AQST this morning and each of my buys was higher than previous. Up only 1.5% RHRN but believe that it will have some good upside from here.
- Lou: The problem with trading around biotech positions is that one never knows when a catalyst will hit. I look at this part of my portfolio as "buy and hold." Really two decision points - buy or sell. I trimmed some $IOVA a couple of days ago and on the next day I bought all back at about the same price. Today, I'm glad that I did.
- woodman: @Lou $IOVA - That and another thing. There are so many irrational dumps of biotechs that in actuality become very good buy points. For example, failures to understand the data that initially are interpreted as bad but then turn out not to be after smart folks really pick it apart (I'm not smart enough to do that, but I can keep watch of what the really smart folks say and take it from there). And stops can really screw with you when you have a long term mentality with biotechs. Trading, of course, is a different animal. There's room for both of course. Just need to know which you want long term and have faith in as an investment, and which you're just in for a trade.
- MongosPawn: $IOVA Took some profits here. Holding the rest thru earnings call scheduled for 2/28.
- woodman: @MongosPawn $IOVA - Still in. It looks like it wants to move up out of this flag. If not today, soon.
- woodman: $IOVA flag/breath-catching.
- kenb: @woodman $IOVA seems to be building a high base after FDA approval, with support at $15. Still outside the upper bollinger band so it will need a little rest allowing the bollinger band to enclose it again. Still holding.
- woodman: @kenb $IOVA - Recent PT raises: Stifel to $28, Baird to $26, Wells Fargo to $22. Always with grains of salt.
- Lou: Took some profits on $IOVA
- jwstich: @woodman what are you planning to do with $IOVA? The stock is down on volume today but I'm not sure if this means anything, Would appreciate your thoughts.
- DavidK: @jwstich $IOVA I sold mine first thing this am for just a little over $1 profit per share . Didn’t like the action.
- woodman: @jwstich $IOVA - I'm still holding. I don't know what today means other than a move above the top BB at 3 standard deviations is virtually impossible to hold up for long. My position is small relative to my core biotech holdings. I don't regard this as a core holding of mine. Because position is relatively small, I may be inclined to add on a pullback. My brain is occupied with other things today, particularly on the $ARDX report and conference call amc, and $SMCI. :-)
- Lou: @woodman $IOVA in the category of "fools rush in...." I'm adding.
- woodman: @Lou $IOVA - LOL!
- Lou: @woodman $IOVA - I like to take my chances on opportunistic entries and I consider $IOVA right around now a decent buy. My approach is one of patience and I need a reason that I clearly understand to bail on a position in which I believe. I make a lousy swing trader and I know it, but my patience pays off more often than not. IMO knowing yourself, your tendencies, as well as your strengths and weaknesses pays you well as an investor/trader.
- woodman: @Lou $IOVA - 100%
- jwstich: @woodman $IOVA $ARDX $SMCI Thanks for your opinion and quick response.
- kenb: @Lou $IOVA Amen.
- camaro69: $IOVA large insider purchases. stock rocketing.
- traderbren: @camaro69 $IOVA - yep, fair amount of interest in the 23 Feb 15 calls today. NP
- woodman: @camaro69 $IOVA - Yes, indeed. And I think what they did in setting up those buys was unsavory ... if not possibly illegal. But stock price doesn't care.
- Lou: @woodman $IOVA - glad I finally got aboard last week and added twice today.
- woodman: @Lou $IOVA - I got a little wrapped around the axle on my IOVA trade(s) but back in yesterday after reading a lot over the weekend. I am convinced there was insider shady effery here. If I were to lay out what I believe they did, I think you'd agree. But it is what it is, short of suing them for it. If you can't beat them, join them.
- Margi1983: @Lou $IOVA Thank you for $FTI. Moving well and because of you, Lou, my cost is way down at 13.45. LT investment
- Margi1983: @woodman $IOVA I missed this one. I will look for a starter at the pivot of 12.25 if there is a pullback
- Lou: @Margi1983 $IOVA $FTI - you're welcome @Margi. Now that you're at a young retirement age, think about dipping your toe into $ET and/or $EPD.
- Margi1983: @Lou $IOVA $FTI $ET $EPD I am 68 and retiring this November. I need you to explain the logic of not holding MLP's in IRA/SEP accounts. Are you suggesting them only for taxable accounts because of the tax deferment?
- camaro69: @woodman $IOVA looks shady!
- Lou: @Margi1983 $IOVA $FTI $ET $EPD - tax deferment is the second reason. The first and more important reason is that earnings by the MLPs i recommend are subject to tax on unrelated business income (UBTI) and these MLPs generate a ton of such taxable income. They more than eat up your profits and appreciation.
- jwstich: @woodman $IOVA Not the first company to do this. Knowing the fundamentals helps a great deal in suspecting this situation.
- Margi1983: @Lou $IOVA $FTI $ET $EPD Got it. I will dip my toe with $EPD on a pullback via my taxable account, not my IRA's, per your advice. I am sure my CPA will hate the tax work, but that's what I pay him for
- Lou: @Margi1983 $IOVA $FTI $ET $EPD - Good luck. The tax accounting is not at all difficult for knowledgeable CPAs. The K-1s and tax support from the MLPs are excellent.
| Stock Price | $5.13 |
| Change | 12.01% |
| Volume | 44,479,700 |
Lion Biotechnologies Inc is a biopharmaceutical company in the United States. Its lead pipeline candidate, LN-144, uses the tumor-infiltrating lymphocytes to treat serious diseases.
Request Video of IOVAAlready a member? Sign in here.
Past Month
Leading Peers
-
$6.52 181.66%
-
$5.30 166.77%
-
$5.13 77.22%
Past Month
Lagging Peers
-
$14.82 -159.13%
-
$14.27 -54.05%
-
$6.81 -48.58%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!